Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Leavitt AD, Mahlangu J, Raheja P, Symington E, Quon DV, Giermasz A, Kenet G, Lowe G, Key NS, Millar CM, Pipe SW, Chou SC, Klamroth R, Mason J, Chambost H, Peyvandi F, Majerus E, Pepperell D, Tan CW, Yu H, Chavele KM, Ozelo MC

Open source

DOI: 10.1016/j.rpth.2026.103416
Published: 2026 Mar
Container: Research and practice in thrombosis and haemostasis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.rpth.2026.103416,
  title = {Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.},
  author = {Leavitt AD and Mahlangu J and Raheja P and Symington E and Quon DV and Giermasz A and Kenet G and Lowe G and Key NS and Millar CM and Pipe SW and Chou SC and Klamroth R and Mason J and Chambost H and Peyvandi F and Majerus E and Pepperell D and Tan CW and Yu H and Chavele KM and Ozelo MC},
  year = {2026},
  journal = {Research and practice in thrombosis and haemostasis},
  doi = {10.1016/j.rpth.2026.103416},
  url = {https://doi.org/10.1016/j.rpth.2026.103416}
}

RIS

TY  - JOUR
TI  - Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.
AU  - Leavitt AD
AU  - Mahlangu J
AU  - Raheja P
AU  - Symington E
AU  - Quon DV
AU  - Giermasz A
AU  - Kenet G
AU  - Lowe G
AU  - Key NS
AU  - Millar CM
AU  - Pipe SW
AU  - Chou SC
AU  - Klamroth R
AU  - Mason J
AU  - Chambost H
AU  - Peyvandi F
AU  - Majerus E
AU  - Pepperell D
AU  - Tan CW
AU  - Yu H
AU  - Chavele KM
AU  - Ozelo MC
PY  - 2026
JO  - Research and practice in thrombosis and haemostasis
DO  - 10.1016/j.rpth.2026.103416
UR  - https://doi.org/10.1016/j.rpth.2026.103416
ER  -

APA

AD, L., J, M., P, R., E, S., DV, Q., A, G., G, K., G, L., NS, K., CM, M., SW, P., SC, C., R, K., J, M., H, C., F, P., E, M., D, P., CW, T., H, Y., KM, C., & MC, O. (2026). Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.. Research and practice in thrombosis and haemostasis. https://doi.org/10.1016/j.rpth.2026.103416

Source records

pubmed · retrieved 2026-09-26T12:06:08.362Z